Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
(China) Biocon (India) Altimmune (US) Viking Therapeutics (US) Recent Industry Developments January 2026: Novo Nordisk received US and EU regulatory approval for Wegovy High-Dose (7.2 mg), expanding treatment options within its obesity portfolio
Throughout your journey, our team offers personalized guidance on self-injection techniques, ongoing monitoring, and motivational support to help you achieve your weight loss goals
The sponsors had no involvement in any aspect of this review, including its conception, literature selection, analysis, manuscript preparation, review, approval, or the decision to publish
Rizzo, M., Rizvi, A
Higher-dose formulations of semaglutide (Wegovy, 2.4 mg weekly) and tirzepatide (Zepbound, up to 15 mg weekly) are approved specifically for chronic weight management in non-diabetic patients
Considering GLP-1 Medications
US$ 22.75
US$ 28.18
US$ 21.15
US$ 29.81
US$ 21.93
US$ 20.83
US$ 20.88
US$ 22.11
US$ 24.81
